GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

Nasus Pharma NSRX · USD

N/A · US listing · 🇺🇸 United States

Compare

2.94

+4.26%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Net income

−$5.9m

FY2022FY2025

Free cash flow

−$4.9m

FY2022FY2025

Shareholders' equity

$2.8m

FY2022FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022
Research and development$2.2m$335,000$567,000$1.1m
Operating income−$4.9m−$1.1m−$1.1m−$2.0m
Net income−$5.9m−$1.5m−$1.1m−$1.7m
Diluted earnings per share-0.65-0.21-0.15-0.15

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022
Total assets$5.0m$717,000$444,000$417,000
Cash and short-term investments$4.3m———
Total liabilities$2.2m$3.9m$4.2m$3.2m
Debt$118,000———
Shareholders' equity$2.8m−$3.2m−$3.8m−$2.8m
Shares outstanding9m7m7m11m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022
Cash from operations−$4.9m−$665,000−$1.0m−$1.2m
Capital spending−$14,000———
Free cash flow−$4.9m−$665,000−$1.0m−$1.2m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Mar 2025Dec 2024Sept 2024Jun 2024
Operating income−$6.0m−$3.0m−$1.2m−$408,500−$408,500−$297,500−$297,500−$241,500
Net income−$5.9m−$3.0m−$1.4m−$626,000−$626,000−$330,500−$330,500−$435,500
Diluted earnings per share-0.54-0.27-0.15-0.07-0.07-0.05-0.05-0.06
Cash from operations−$1.0m—−$1.0m—————
Total assets$12.4m$12.4m$5.0m$5.0m—$717,000—$1.0m
Cash and short-term investments$11.8m$11.8m$4.3m$4.3m—$284,000—$900,000
Debt$54,000$54,000$45,000$45,000—$1.8m—$3.8m
Shareholders' equity$11.0m$11.0m$2.8m$2.8m—−$3.2m—−$4.7m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income33.9%——
Net income50.7%——

Valuation history

At each fiscal year end

FY2025
Price to earnings-8.7

Share price return

Finished calendar years

2025
Return-23%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.